BACKGROUND: Smoking, alcohol use, and obesity appear to increase the risk of developing non-Hodgkin lymphoma (NHL), but to the authors' knowledge, few studies to date have assessed their impact on NHL prognosis. METHODS: The association between prediagnosis cigarette smoking, alcohol use, and body mass index (BMI) and overall survival was evaluated in 1286 patients enrolled through population-based registries in the United States from 1998 through 2000. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using Cox regression, adjusting for clinical and demographic factors. RESULTS: Through 2007, 442 patients had died (34%), and the median follow-up for surviving patients was 7.7 years. Compared with never smokers, former (HR, 1.59; 95% CI, 1.12-2.26) and current (HR, 1.50; 95% CI, 0.97-2.29) smokers had poorer survival, and poorer survival was found to be positively associated with smoking duration, number of cigarettes smoked per day, pack-years of smoking, and shorter time since quitting (all P <0.01). Alcohol use was associated with poorer survival (P = 0.03); compared with nonusers. Those drinking >43.1 g/week (median intake among drinkers) had poorer survival (HR, 1.55; 95% CI, 1.06-2.27), whereas those drinkers consuming less than this amount demonstrated no survival disadvantage (HR, 1.13; 95% CI, 0.75-1.71). Greater BMI was associated with poorer survival (P = 0.046), but the survival disadvantage was only noted among obese individuals (HR, 1.32 for BMI > or = 30 vs BMI 20-24.9; 95% CI, 1.02-1.70). These results held for lymphoma-specific survival and were broadly similar for diffuse large B-cell lymphoma and follicular lymphoma. CONCLUSIONS: NHL patients who smoked, consumed alcohol, or were obese before diagnosis were found to have a poorer overall and lymphoma-specific survival.
BACKGROUND: Smoking, alcohol use, and obesity appear to increase the risk of developing non-Hodgkin lymphoma (NHL), but to the authors' knowledge, few studies to date have assessed their impact on NHL prognosis. METHODS: The association between prediagnosis cigarette smoking, alcohol use, and body mass index (BMI) and overall survival was evaluated in 1286 patients enrolled through population-based registries in the United States from 1998 through 2000. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using Cox regression, adjusting for clinical and demographic factors. RESULTS: Through 2007, 442 patients had died (34%), and the median follow-up for surviving patients was 7.7 years. Compared with never smokers, former (HR, 1.59; 95% CI, 1.12-2.26) and current (HR, 1.50; 95% CI, 0.97-2.29) smokers had poorer survival, and poorer survival was found to be positively associated with smoking duration, number of cigarettes smoked per day, pack-years of smoking, and shorter time since quitting (all P <0.01). Alcohol use was associated with poorer survival (P = 0.03); compared with nonusers. Those drinking >43.1 g/week (median intake among drinkers) had poorer survival (HR, 1.55; 95% CI, 1.06-2.27), whereas those drinkers consuming less than this amount demonstrated no survival disadvantage (HR, 1.13; 95% CI, 0.75-1.71). Greater BMI was associated with poorer survival (P = 0.046), but the survival disadvantage was only noted among obese individuals (HR, 1.32 for BMI > or = 30 vs BMI 20-24.9; 95% CI, 1.02-1.70). These results held for lymphoma-specific survival and were broadly similar for diffuse large B-cell lymphoma and follicular lymphoma. CONCLUSIONS: NHL patients who smoked, consumed alcohol, or were obese before diagnosis were found to have a poorer overall and lymphoma-specific survival.
Authors: Thomas M Habermann; Sophia S Wang; Matthew J Maurer; Lindsay M Morton; Charles F Lynch; Stephen M Ansell; Patricia Hartge; Richard K Severson; Nathaniel Rothman; Scott Davis; Susan M Geyer; Wendy Cozen; Stephen J Chanock; James R Cerhan Journal: Blood Date: 2008-07-16 Impact factor: 22.113
Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245
Authors: C Tarella; D Caracciolo; P Gavarotti; C Argentino; F Zallio; P Corradini; D Novero; C Magnani; A Pileri Journal: Bone Marrow Transplant Date: 2000-12 Impact factor: 5.483
Authors: James R Cerhan; Wen Liu-Mares; Zachary S Fredericksen; Anne J Novak; Julie M Cunningham; Neil E Kay; Ahmet Dogan; Mark Liebow; Alice H Wang; Timothy G Call; Thomas M Habermann; Stephen M Ansell; Susan L Slager Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254
Authors: Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Priyanka A Pophali; Andrew Ip; Melissa C Larson; Allison C Rosenthal; Matthew J Maurer; Christopher R Flowers; Brian K Link; Umar Farooq; Andrew L Feldman; Cristine Allmer; Susan L Slager; Thomas E Witzig; Thomas M Habermann; Jonathon B Cohen; James R Cerhan; Carrie A Thompson Journal: Am J Hematol Date: 2018-10-17 Impact factor: 10.047
Authors: Nicholas J Ollberding; Andrew M Evens; Briseis Aschebrook-Kilfoy; Donne Bennett D Caces; Dennis D Weisenburger; Sonali M Smith; Brian C-H Chiu Journal: Br J Haematol Date: 2013-08-02 Impact factor: 6.998
Authors: Dai Chihara; Loretta J Nastoupil; Jessica N Williams; Paul Lee; Jean L Koff; Christopher R Flowers Journal: Expert Rev Anticancer Ther Date: 2015-04-11 Impact factor: 4.512
Authors: Michael E Williams; Joseph M Connors; Martin H Dreyling; Randy D Gascoyne; Brad S Kahl; John P Leonard; Oliver W Press; Wyndham H Wilson Journal: Leuk Lymphoma Date: 2010-12-06
Authors: Kisha I Coa; Katherine Clegg Smith; Ann C Klassen; Laura E Caulfield; Kathy Helzlsouer; Kim Peairs; Lillie Shockney Journal: Support Care Cancer Date: 2014-08-28 Impact factor: 3.603